Metformin: Do we finally have an anti-aging drug?

PFO and cryptogenic stroke: Do we finally have closure?

In up to 40 percent of patients with acute ischemic stroke, the etiology remains uncertain [1]. The association of a PFO with stroke in a young woman with cerebral arterial embolism was first described in 1877 [2]. Lechat et al. later described the high prevalence of PFO in adults younger than 55 years of age when no identifiable cause of stroke could be identified [3]. They suggested that para...

Adjuvant treatment for renal cell carcinoma: do we finally have a major breakthrough?

Clinical parameters can be used to identify patients at greatest risk for recurrence following nephrectomy for clinically localized renal cell carcinoma (RCC). Molecular tools are being developed to improve risk stratification. An increasing list of available treatments for metastatic RCC continues to provide hope that an effective adjuvant therapy will be identified for patients with high-risk...

Selective allodepletion: have we finally found the holy grail?

Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment option for patients with hematologic malignancies and nonmalignant disorders of hematopoiesis. Outcomes of allogeneic HSCT have improved steadily over the decades [1]. However, significant challenges remain. One of these challenges is the so-called Holy Grail of stem cell transplantation immunology: to...

Aromatase Inhibitors for Endometriosis-Associated Infertility; Do We Have Sufficient Evidence?

Orally active aromatase inhibitors (AIs) have gained attention for treatment of infertile women with endometriosis in whom aromatase p450 is aberrantly expressed. This review aimed to critically appraise and summarize the available evidence concerning the use of AIs for management of endometriosis-associated infertility. PubMed was searched to May 2015 with the following key words: endometriosi...

Predicting Fault-Proneness: Do We Finally Know How?